Back to List View Graph View

KLF4

KLF4 (Krüppel-like factor 4) is a transcription factor implicated in the regulation of epithelial integrity, endothelial function, immune-cell state, vascular smooth-muscle phenotype, and cellular responses to oxidative stress and ferroptosis.

Where the papers sit

8 papers from the last 6 months study KLF4 directly · updated from PubMed 11 Nov 2026

Study type 0 clinical trials · 8 preclinical

Themes one subject

Those 8 are all about one subject.

  • Context-Dependent Disease Biology

    Disease mechanisms range from endothelial exosome-driven chromatin remodeling and metastatic colonization to ferroptosis in diabetic tubular injury. Other work addresses immune evasion in esophageal cancer, metabolic syndrome, neurovascular aging, and CAR-T-cell exhaustion. Therapeutic studies test valproic acid, zebularine, and KLF4-enhanced CAR-T cells, but no shared intervention or endpoint recurs. The cluster therefore has no unified direction beyond broad interest in disease-associated molecular regulation.

    8 papers

Papers

The 8 papers from the last 6 months that study KLF4 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Context-Dependent Disease Biology (8)
  1. Endothelial exosomes remodel chromatin accessibility and superenhancer in cancer cells to promote liver metastatic colonization. Signal transduction and targeted therapy · 18 Oct 2026 PMID 42894010
  2. A Barrier Betrayed: Hillock in Lung Squamous Cell Carcinoma. Cancer research · 15 Sept 2026 PMID 42740576
  3. miR-145-5p Targets KLF4 to Regulate the SIRT3/GPX4 Axis, Mediating Ferroptosis and Exacerbating Tubular Epithelial Cell Injury in Diabetic Nephropathy. Nephrology (Carlton, Vic.) · 24 Jul 2026 PMID 42494277
  4. Krüppel-like factor 4 downregulation during esophageal cancer formation facilitates immune evasion and impairs immunotherapy. Signal transduction and targeted therapy · 23 Jul 2026 PMID 42493491
  5. Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome. Cell host & microbe · 1 Jul 2026 PMID 42385714
  6. Endothelial KLF4 depletion drives age-related neurovascular dysfunction and neuropsychiatric impairment. Proceedings of the National Academy of Sciences of the United States of America · 18 Jun 2026 PMID 42313933
  7. Combinatorial drug repurposing of Valproic acid and Zebularine regulates Krüppel-like factor 4 and β-catenin expression in colon cancer cells. PloS one · 1 Jun 2026 PMID 42224286
  8. KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion. Journal for immunotherapy of cancer · 20 May 2026 PMID 42161404

By study type

Preclinical: animal, cell and lab studies (8)
  1. Endothelial exosomes remodel chromatin accessibility and superenhancer in cancer cells to promote liver metastatic colonization. Signal transduction and targeted therapy · 18 Oct 2026 PMID 42894010
  2. A Barrier Betrayed: Hillock in Lung Squamous Cell Carcinoma. Cancer research · 15 Sept 2026 PMID 42740576
  3. miR-145-5p Targets KLF4 to Regulate the SIRT3/GPX4 Axis, Mediating Ferroptosis and Exacerbating Tubular Epithelial Cell Injury in Diabetic Nephropathy. Nephrology (Carlton, Vic.) · 24 Jul 2026 PMID 42494277
  4. Krüppel-like factor 4 downregulation during esophageal cancer formation facilitates immune evasion and impairs immunotherapy. Signal transduction and targeted therapy · 23 Jul 2026 PMID 42493491
  5. Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome. Cell host & microbe · 1 Jul 2026 PMID 42385714
  6. Endothelial KLF4 depletion drives age-related neurovascular dysfunction and neuropsychiatric impairment. Proceedings of the National Academy of Sciences of the United States of America · 18 Jun 2026 PMID 42313933
  7. Combinatorial drug repurposing of Valproic acid and Zebularine regulates Krüppel-like factor 4 and β-catenin expression in colon cancer cells. PloS one · 1 Jun 2026 PMID 42224286
  8. KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion. Journal for immunotherapy of cancer · 20 May 2026 PMID 42161404